Octapharma recalls Octagam lot in US

By Gareth Macdonald

- Last updated on GMT

Octapharma facility in Vienna, Austria
Octapharma facility in Vienna, Austria

Related tags Immune system

Octapharma has withdrawn one lot of its immune deficiency treatment Octagam after receiving reports of reports of allergic skin reactions in patients treated with the product.

The Swiss firm’s US unit – Octapharma USA – said​ the recall only affected one lot of Octagam Immune Globulin Intravenous (Human) 5% - number K551A8441 – that was made at its facility in Vienna, Austria.

Although there have been no reports of serious injury at this time, Octapharma has determined, through consultation with the public health authorities at FDA, the most prudent course of action is to suspend further administration of this Octagam from this production lot.”

Octapharma did not respond to a request for comment.

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers